Journal of Medicinal Chemistry · 2012 · 15 citations · 23 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryLead OptimizationEnzyme InhibitionHit-to-lead OptimizationLead Compound DesignPotency OptimizationStructure-activity Relationship AnalysisChemical Synthesis Of AnaloguesFocused Combinatorial Library DesignFocused Library SynthesisHuman Ether-a-go-go-related Gene (Herg) Channel InhibitionLead Series OptimizationMedicinal Chemistry ApplicationsNeuroactive CompoundsPatch Clamp Techniques
Numerous studies have shown that selective nNOS inhibitors could be therapeutic in many neurological disorders. Previously, we reported a series of 1,2,3,4-tetrahydroquinoline-based potent and selective nNOS inhibitors, highlighted by 1 ( J. Med. Chem. 2011 , 54 , 5562 - 5575 ). Despite showing activity in two rodent pain models, 1 suffered from low oral bioavailability (18%) and moderate hERG channel inhibition (IC(50) = 4.7 μM). To optimize the properties of 1, we synthesized a small focused library containing various alkylamino groups on the 1-position of the 1,2,3,4-tetrahydroquinoline scaffold. The compounds were triaged based on their activity in the NOS and hERG manual patch clamp assays and their calculated physicochemical parameters. From these studies, we identified 47 as a potent and selective nNOS inhibitor with improved oral bioavailability (60%) and no hERG channel inhibition (IC(50) > 30 μM). Furthermore, 47 was efficacious in the Chung model of neuropathic pain and has an excellent safety profile, making it a promising preclinical development candidate.
23
Hypertension in mice lacking the gene for endothelial nitric oxide synthase
Paul L. Huang, Zhihong Huang, Hiroshi Mashimo et al. · Nature · 1995 · 2.1K citations
Life Sciences, Genetics, Physiology +12
Travis T. Wager, Xinjun Hou, Patrick R. Verhoest et al. · ACS Chemical Neuroscience · 2010 · 1K citations